サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1207169

RWE（リアルワールドエビデンス）ソリューション市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年の予測

Real-World Evidence Solutions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
RWE（リアルワールドエビデンス）ソリューション市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年の予測
出版日: 2023年01月31日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリアルワールド・エビデンス・ソリューションの市場規模は、2022年に16億米ドルに達しました。今後、IMARCグループは、2023年から2028年の間に8.57%の成長率（CAGR）を示し、2028年までに27億米ドルに達すると予測しています。

リアルワールドエビデンス（RWE）とは、リアルワールドデータ（RWD）を通じて、医療製品の使用および潜在的な利益またはリスクに関する臨床エビデンスを指します。RWEは、無作為化試験、大規模単純試験、プラグマティック試験、観察研究など、さまざまな研究デザインや分析を通じて作成することができます。RWDは、投与量、コンプライアンス、アドヒアランス、適応外使用、有効性と安全性のバランスなど、患者グループにおける現実の治療パターンに関する洞察を提供します。また、研究者が可能性のある患者を発見し、臨床試験の正しい組み入れ基準を作成することで、より良い治験前試験の設計を支援できることから、世界中でRWEソリューションの需要が高まっています。

リアルワールド・エビデンス・ソリューションの市場動向

  • 新製品の安全性と有効性に関する正確で明確な情報を得るためのRWEソリューションに対する需要の高まりは、市場を牽引する重要な要因の1つとなっています。さらに、複雑で合併症のある患者が使用する際の様々な反応、製品サブポピュレーション効果、製品価値を検出するためのこれらのソリューションに対する需要も高まっています。このことは、急成長するヘルスケア産業とともに、市場の成長を促進しています。さらに、臨床開発、商業化、スピードイノベーション、ヘルスケア成果の改善の加速のために、RWEにおける高度な分析と技術ソリューションの活用が拡大していることも、市場にプラスの影響を与えています。これに加えて、医薬品やワクチンの有効性を提供するRWEソリューションの利用を促進するために、いくつかの国の政府別様々なイニシアチブが実施されています。これは、量に基づくケアから価値に基づくケアへのシフトと相まって、業界の投資家に有利な成長機会を提供しています。これとは別に、デジタル化と患者中心のバーチャルケアの採用が拡大していることが、RWEソリューションの需要を促進しています。さらに、がん、肥満、糖尿病などの慢性疾患の有病率が世界的に上昇しています。これに伴い、医薬品開発の遅延の増加やそれに伴う開発コストの増大が、市場の成長を後押ししています。

主要市場のセグメンテーション

  • IMARC Groupでは、世界のリアルワールドエビデンスソリューション市場のレポートにおいて、2023年から2028年までの世界、地域、国レベルでの予測とともに、各サブセグメントにおける主要動向の分析を行っています。当レポートでは、コンポーネント、治療分野、エンドユーザーに基づいて市場を分類しています。

コンポーネント別の内訳

  • 臨床設定データ
  • クレームデータ
  • 患者主導型データ
  • 薬局データ
  • その他

治療分野別内訳

  • オンコロジー
  • 免疫学
  • 神経領域
  • 循環器領域
  • その他

エンドユーザー別内訳

  • 製薬会社、医療機器メーカー
  • ヘルスケアペイヤー
  • ヘルスケアプロバイダー
  • その他

地域別の内訳

  • 北米
  • 米国
  • カナダ
  • アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
  • 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
  • 中東とアフリカ

本レポートで回答した主な質問

  • 世界のリアルワールドエビデンスソリューション市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19は世界のリアルワールドエビデンスソリューション市場にどのような影響を与えたか？
  • 主要な地域市場とは？
  • 構成要素に基づく市場の内訳は？
  • 治療分野別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々なステージとは？
  • 業界における主要な促進要因と課題は何か？
  • 世界のリアルワールドエビデンスソリューションの市場構造と主要プレイヤーは？
  • 業界における競合の度合いとは？

目次

第1章 序文

第2章 調査手法と範囲

  • 調査の目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な産業動向

第5章 実世界エビデンスソリューションの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 コンポーネント別市場内訳

  • 臨床現場データ
    • 市場動向
    • 市場予測
  • クレームデータ
    • 市場動向
    • 市場予測
  • 患者情報データ
    • 市場動向
    • 市場予測
  • 薬局データ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 治療領域別市場内訳

  • オンコロジー
    • 市場動向
    • 市場予測
  • 免疫領域
    • 市場動向
    • 市場予測
  • 神経領域
    • 市場動向
    • 市場展望
  • 循環器領域
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 エンドユーザー別市場内訳

  • 製薬・医療機器メーカー
    • 市場動向
    • 市場予測
  • ヘルスケアペイヤー
    • 市場動向
    • 市場予測
  • ヘルスケアプロバイダ
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場展望
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場展望
    • 日本
      • 市場動向
      • 市場展望
    • インド
      • 市場動向
      • 市場展望
    • 韓国市場
      • 市場動向
      • 市場展望
    • オーストラリア
      • 市場動向
      • 市場展望
    • インドネシア
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場展望
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場展望
    • スペイン
      • 市場動向
      • 市場展望
    • ロシア
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場展望
    • メキシコ
      • 市場動向
      • 市場展望
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場展望

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターズファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競争情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Aetion Inc.
    • Clinigen Limited
    • Flatiron Health Inc.（Roche Holding AG）
    • ICON plc
    • International Business Machines Corporation
    • IQVIA
    • Optum Inc.（UnitedHealth Group Incorporated）
    • Oracle Corporation
    • Parexel International Corporation
    • PPD Inc.（Thermo Fisher Scientific Inc.）
    • Sas Institute Inc.
    • Syneos Health
図表

List of Figures

  • Figure 1: Global: Real-World Evidence Solutions Market: Major Drivers and Challenges
  • Figure 2: Global: Real-World Evidence Solutions Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Real-World Evidence Solutions Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Real-World Evidence Solutions Market: Breakup by Component (in %), 2022
  • Figure 5: Global: Real-World Evidence Solutions Market: Breakup by Therapeutic Area (in %), 2022
  • Figure 6: Global: Real-World Evidence Solutions Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Real-World Evidence Solutions Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Real-World Evidence Solutions (Clinical Settings Data) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Real-World Evidence Solutions (Clinical Settings Data) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Real-World Evidence Solutions (Claims Data) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Real-World Evidence Solutions (Claims Data) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Real-World Evidence Solutions (Patient-Powered Data) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Real-World Evidence Solutions (Patient-Powered Data) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Real-World Evidence Solutions (Pharmacy Data) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Real-World Evidence Solutions (Pharmacy Data) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Real-World Evidence Solutions (Other Components) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Real-World Evidence Solutions (Other Components) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Real-World Evidence Solutions (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Real-World Evidence Solutions (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Real-World Evidence Solutions (Immunology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Real-World Evidence Solutions (Immunology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Real-World Evidence Solutions (Neurology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Real-World Evidence Solutions (Neurology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Real-World Evidence Solutions (Cardiovascular Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Real-World Evidence Solutions (Cardiovascular Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Real-World Evidence Solutions (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Real-World Evidence Solutions (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Real-World Evidence Solutions (Pharmaceutical and Medical Device Companies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Real-World Evidence Solutions (Pharmaceutical and Medical Device Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Real-World Evidence Solutions (Healthcare Payers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Real-World Evidence Solutions (Healthcare Payers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Real-World Evidence Solutions (Healthcare Providers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Real-World Evidence Solutions (Healthcare Providers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Real-World Evidence Solutions (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Real-World Evidence Solutions (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: North America: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: North America: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: United States: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: United States: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Canada: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Canada: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Asia-Pacific: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Asia-Pacific: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: China: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: China: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Japan: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Japan: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: India: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: India: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: South Korea: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: South Korea: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Australia: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Australia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Indonesia: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Indonesia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Others: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Europe: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Europe: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Germany: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Germany: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: France: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: France: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: United Kingdom: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: United Kingdom: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Italy: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Italy: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Spain: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Spain: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Russia: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Russia: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Latin America: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Latin America: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Brazil: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Brazil: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Mexico: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Mexico: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Others: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Others: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Middle East and Africa: Real-World Evidence Solutions Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Middle East and Africa: Real-World Evidence Solutions Market: Breakup by Country (in %), 2022
  • Figure 84: Middle East and Africa: Real-World Evidence Solutions Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Global: Real-World Evidence Solutions Industry: SWOT Analysis
  • Figure 86: Global: Real-World Evidence Solutions Industry: Value Chain Analysis
  • Figure 87: Global: Real-World Evidence Solutions Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Real-World Evidence Solutions Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Real-World Evidence Solutions Market Forecast: Breakup by Component (in Million US$), 2023-2028
  • Table 3: Global: Real-World Evidence Solutions Market Forecast: Breakup by Therapeutic Area (in Million US$), 2023-2028
  • Table 4: Global: Real-World Evidence Solutions Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Real-World Evidence Solutions Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Real-World Evidence Solutions Market: Competitive Structure
  • Table 7: Global: Real-World Evidence Solutions Market: Key Players
目次
Product Code: SR1323A641_Report

The global real-world evidence solutions market size reached US$ 1.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.7 Billion by 2028, exhibiting a growth rate (CAGR) of 8.57% during 2023-2028.

Real-world evidence (RWE) refers to clinical evidence about the use and potential benefits or risks of medical products via real-world data (RWD). It can be produced via different study designs or analyses, including randomized trials, big simple trials, pragmatic trials, and observational studies. It provides insight into real-world treatment patterns in patient groups, including dosing, compliance, adherence, off-label use, and the balance between efficacy and safety. As it can also assist researchers in discovering possible patients and developing correct inclusion criteria for clinical trials, which can help them design better pre-trial studies, there is a rise in the demand for RWE solutions around the world.

Real-World Evidence Solutions Market Trends:

  • The growing demand for RWE solutions to get precise and clear information about the safety and efficacy of new products represents one of the key factors driving the market. Moreover, there is a rise in the demand for these solutions to detect varied reactions, product subpopulation effects, and product value when utilized by complex and comorbid patients. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Additionally, the growing utilization of advanced analytics and technological solutions in RWE for clinical development, commercialization, speed innovation, and accelerating improvements in healthcare outcomes is positively influencing the market. Besides this, there are various initiatives undertaken by governments of several countries to promote the use of RWE solutions, which provide the efficacy of drugs and vaccines. This, coupled with a shift from volume to value-based care, is offering lucrative growth opportunities to industry investors. Apart from this, the growing adoption of digitalization and patient-centered virtual care is catalyzing the demand for RWE solutions. Furthermore, there is an increase in the prevalence of chronic diseases, such as cancer, obesity, and diabetes, across the globe. In line with this, the rising delays in drug development and the subsequent increase in development costs are bolstering the growth of the market.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global real-world evidence solutions market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, therapeutic area and end user.

Breakup by Component:

  • Clinical Settings Data
  • Claims Data
  • Patient-Powered Data
  • Pharmacy Data
  • Others

Breakup by Therapeutic Area:

  • Oncology
  • Immunology
  • Neurology
  • Cardiovascular Disease
  • Others

Breakup by End User:

  • Pharmaceutical and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined along with the profiles of the key players being Aetion Inc., Clinigen Limited, Flatiron Health Inc. (Roche Holding AG), ICON plc, International Business Machines Corporation, IQVIA, Optum Inc. (UnitedHealth Group Incorporated), Oracle Corporation, Parexel International Corporation, PPD Inc. (Thermo Fisher Scientific Inc.), Sas Institute Inc. and Syneos Health.

Key Questions Answered in This Report:

  • How has the global real-world evidence solutions market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global real-world evidence solutions market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global real-world evidence solutions market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Real-World Evidence Solutions Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Clinical Settings Data
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Claims Data
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Patient-Powered Data
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Pharmacy Data
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Immunology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cardiovascular Disease
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Pharmaceutical and Medical Device Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Healthcare Payers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Healthcare Providers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aetion Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Clinigen Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Flatiron Health Inc. (Roche Holding AG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 ICON plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 International Business Machines Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 IQVIA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Optum Inc. (UnitedHealth Group Incorporated)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Oracle Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Parexel International Corporation
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 PPD Inc. (Thermo Fisher Scientific Inc.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Sas Institute Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 SWOT Analysis
    • 14.3.12 Syneos Health
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis